单克隆抗体治疗炎性肠病耐药的研究进展  

Research advances in monoclonal antibodies for treatment of drug resistance in inflammatory bowel disease

作　　者：顾家博 韦平(综述)[1] 王俊 金黑鹰(审校)[3] GU Jiabo;WEI Ping;WANG Jun;JIN Heiying(Anorectal Department,Lianyungang Hospital of Traditional Chinese Medicine,Lianyungang 222004,Jiangsu Province,China;不详)

机构地区：[1]连云港市中医院肛肠科,江苏连云港222004 [2]南京中医药大学第二临床医学院,江苏南京210029 [3]江苏省第二中医院肛肠科,江苏南京210017

出　　处：《中国生物制品学杂志》2024年第2期251-256,共6页Chinese Journal of Biologicals

基　　金：江苏省自然科学基金面上项目(BK20191502)。

摘　　要：炎性肠病(inflammatory bowel disease,IBD)是由免疫介导的一种复杂性炎性疾病,该病的治疗以维持疾病缓解和预防复发为目标。随着对炎性肠病发生发展分子机制的深入研究,发现了许多相关的靶点分子,相应靶点的单克隆抗体(简称单抗)已用于治疗该病,但治疗时产生的耐药现象严重影响治疗效果。本文对英夫利昔等单抗治疗炎性肠病耐药作一综述,以期了解其可能的机理,探索有效的治疗和预防措施。Inflammatory bowel disease(IBD)is a complex inflammatory disease mediated by immunity that is treated with the goal of maintaining disease remission and preventing recurrence.With the deep study of the molecular mechanism of the occurrence and development of IBD,many related target molecules have been found,and the monoclonal antibodies of corresponding targets have been used to treat the disease,while the drug resistance phenomenon generated during treatment has seriously affected the treatment effect.In this paper,monoclonal antibodies such as infliximab were reviewed for the treatment of IBD resistance,with a view to understanding its possible mechanisms and exploring effective treatments and preventive measures.

关 键 词：炎性肠病 单克隆抗体 耐药 

分 类 号：R574[医药卫生—消化系统]